{
    "root": "824033ce-a50b-4914-b0b9-b0005739555c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": "Diclofenac Sodium",
    "value": "20250328",
    "ingredients": [
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS: Gastrointestinal Bleeding, Ulceration and Perforation\n                     ).\n                  Diclofenac sodium delayed-release tablets are indicated:\n                  \n                     For relief of the signs and symptoms of osteoarthritis\n                     For relief of the signs and symptoms of rheumatoid arthritis\n                     For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS: Gastrointestinal Bleeding, Ulceration, and Perforation\n                     ).\n                  After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patientâ€™s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100 to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  For the relief of rheumatoid arthritis, the recommended dosage is 150 to 200 mg/day in divided doses (50 mg three times a day or four times a day, or 75 mg twice a day).\n                  For the relief of ankylosing spondylitis, the recommended dosage is 100 to 125 mg/day, administered as 25 mg four times a day, with an extra 25 mg dose at bedtime if necessary.\n                  Different formulations of diclofenac (diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets; diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions": "75 mg: round, Light brown, enteric-coated tablets P 75 imprinted on one side in black ink and plain on the reverse side\n                  \n                  Product: 71335-0456\n                  NDC: 71335-0456-0 40 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-1 28 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-2 60 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-3 20 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-4 30 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-5 120 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-6 90 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-7 100 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-8 15 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC: 71335-0456-9 14 TABLET, DELAYED RELEASE in a BOTTLE\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients.\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see \n                           WARNINGS: Anaphylactic Reactions\n                        , \n                           Serious Skin Reactions\n                        ).\n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see \n                           WARNINGS: AnaphylacticReaction\n                        , \n                           Exacerbation of Asthma Related to Aspirin Sensitivity\n                        ).\n                     In the setting of coronary artery bypass graft (CABG) surgery (see \n                           WARNINGS: Cardiovascular ThromboticEvents)."
}